Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer

Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J. Langer

Research output: Contribution to journalArticlepeer-review

Abstract

The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK+ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK+ NSCLC patients was limited.

Original languageEnglish (US)
Pages (from-to)49-57
Number of pages9
JournalClinical Lung Cancer
Volume22
Issue number1
DOIs
StatePublished - Jan 2021
Externally publishedYes

Keywords

  • Cancer genomics
  • Immune checkpoint inhibitor
  • Next-generation sequencing
  • Resistance
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non–Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this